# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-25T01:17:05.756819

---

**Idea Fidelity**

The paper remains faithful to the manifest’s core idea. It exploits EO 13771 as a plausibly exogenous regulatory budget shock, measures differential exposure through agencies’ pre-2017 shares of EO 12866–“significant” rulemakings, and estimates continuous DiD effects on duration, completion, and significance composition, with Biden’s EO 13992 rescission serving as a reversal test. The data source, policy timing, key outcomes, and compositional research question match the plan laid out in the manifest. The one area where the paper could be more explicit is in fully describing how the preset significance share is constructed and why it is not contaminated by post-2017 behavior; clarifying that (and potentially reinforcing it with alternative pre-treatment treatment measures) would strengthen fidelity to the identification strategy.

**Summary**

The paper provides the first causal evidence that EO 13771, the Trump-era “two-for-one” regulatory budget, led agencies with many economically significant rules to reclassify their pipelines: their share of EO 12866 “significant” NPRMs fell by roughly 18 percentage points, while overall NPRM volume and completion rates showed only imprecise changes. Using a continuous agency-level DiD with agency and semester fixed effects over 2010–2024 and leveraging Biden’s 2021 rescission as a reversal test, the author argues that the compositional shift persisted post-rescission—suggesting a reclassification ratchet rather than a temporary reaction. These results suggest regulatory budgets influence *what* agencies regulate more than *whether* they regulate.

**Essential Points**

1. **Strengthen evidence for the parallel trends assumption across all outcomes.** The event study presented is only for log(NPRMs), yet the main claim rests on shifts in significance share and duration. The parallel trends assumption should be verified for each primary outcome, particularly the significance share itself, given it drives the key compositional story. If pre-trends differ, the DiD estimates may reflect pre-existing divergence between high- and low-significance agencies rather than an EO13771 effect.

2. **Clarify and defend the pre-determined nature of the treatment measure.** The treatment intensity is the agency’s pre-2017 share of EO 12866 significant rules, but the same designation is the primary outcome. This raises concerns about mechanical correlations and the risk that the treatment measure already encodes the agency’s propensity to declare rules significant for reasons unrelated to EO 13771. It would help to (a) show robustness to alternative pre-treatment measures (e.g., share of economically significant final rules, cost estimates, or the share of NPRMs exceeding a dollar-threshold); (b) demonstrate that the pre-period share is stable over time; and (c) argue why it is plausibly exogenous to the Trump deregulatory agenda aside from the EO.

3. **Address the role of contemporaneous policies and broader deregulatory campaigns.** The Trump administration implemented numerous deregulatory initiatives (e.g., instructions to OIRA, agency-specific reviews) that may have affected high-significance agencies differently, confounding the EO 13771 estimate. The paper needs to either (a) control for or explicitly discuss these concurrent forces, possibly through additional fixed effects or control variables (e.g., agency-specific time trends, indicators for other executive actions, or measures of political salience); (b) provide stronger placebo tests showing that other policy changes in 2017 did not drive the results; or (c) argue convincingly that the differential impact across agencies cannot be attributed to these other policies.

If these issues are not sufficiently addressed, the credibility of the identification strategy is compromised, and I would lean toward rejection.

**Suggestions**

1. **Augment the treatment intensity definition and robustness**. As noted above, the same “significance” label emboldens both treatment and outcome. Consider constructing treatment intensity from alternative, objective pre-2017 margins: (i) the count or share of NPRMs with dollar-estimated economic impacts above $100 million as independently reported; (ii) agency-level shares of NPRMs flagged as “major” or “economically significant” across multiple years, perhaps including Federal Register text searching or metadata outside of the EO 12866 designation; or (iii) budget-relevant proxies such as total regulatory cost estimates or cost-benefit narratives. Demonstrating that results persist with these alternatives would reinforce the interpretation that EO 13771’s bindingness drove the compositional shift rather than the arbitrary classification itself.

2. **Provide richer event studies and dynamic plots.** Supply event-study plots (with confidence intervals) for each outcome, especially significance share, duration, and completion rate. Include the post-rescission window to visually assess persistence or reversal. This will (a) reassure readers about parallel trends and (b) illustrate the timing and magnitude of EO 13771’s impact, particularly regarding the supposed ratchet effect.

3. **Explore mechanisms beyond classification.** The paper argues that agencies reclassified their rules, but the current evidence shows only that the significant share declined. To deepen the mechanistic story, consider:
   - Examining whether the rules that shifted from “significant” to “non-significant” had similar policy content or estimated economic impacts pre- and post-EO by leveraging any available textual or numerical metadata (e.g., RIN, CFR citations, issue area).
   - Assessing whether the EO13771 deregulatory dockets (from Regulations.gov) are concentrated among high-significance agencies, which would support the idea that agencies pursued deregulatory priorities within the EO’s framework.
   - Checking whether agencies that reduced their significance share reallocated resources to deregulatory actions (e.g., final rules flagged as deregulatory, withdrawals) beyond what is captured in the significant-share metric.

4. **Control for alternative policy shocks and offer falsification tests.** In addition to the placebo at 2014, add falsification exercises keyed to other major policy changes. For example, test whether EO 13771’s effect is concentrated only after January 30, 2017 (not January 20, 2017) and whether the effect is absent in non-executive agencies or independent commissions unaffected by EO 13771. Another idea is to interact the treatment with a measure of agency alignment with the President’s policy agenda (e.g., whether agency head was Senate-confirmed post-2017) to test whether the effect is specific to EO 13771 rather than a general shift in agenda.

5. **Address the precision and interpretation of the rescission coefficients.** The post-2021 coefficients have the same sign as the initial treatment, yet the narrative emphasizes the absence of reversal. Clarify whether this persistence is statistically distinguishable from zero or simply imprecise; consider pooling the post-rescission period and testing whether the sum $\beta_1 + \beta_2$ differs from zero. If resurgent effects are concentrated in certain agencies or issue areas, explore heterogeneity (e.g., cabinet vs. independent agencies). Also, connect these estimates to the ratchet theory more explicitly—what institutional frictions would keep agencies from reverting, and how might they manifest in the data?

6. **Enhance the discussion of limitations and alternative explanations.** The conclusion briefly notes limitations; it would be helpful to expand this into a structured subsection that explicitly states what the data cannot rule out (e.g., residual confounding, measurement error, incomplete view of agency behavior) and suggests how future work could address these gaps (e.g., qualitative case studies or richer regulatory cost data). This helps readers contextualize the findings and prepares the ground for subsequent research.

7. **Consider interfacing with OOIRA data or agencies’ internal communications if feasible.** Even if not included in the current draft, mention whether additional qualitative or administrative data (e.g., OIRA’s regulatory budget memos, agency directives) could be used in future iterations to corroborate the empirical findings. If such data are not accessible, stating that upfront avoids questions about selective reporting.

8. **Technical and presentation refinements**. Given the clustered standard errors with only 40 clusters, consider reporting wild-cluster bootstrap p-values or randomization inference to ensure inference is not driven by a few agencies. Also, include more precise definitions of the outcome variables (e.g., how duration is averaged across NPRMs in a semester) and note any handling of missing dates (e.g., NPRMs without matching final rules). Finally, consider moving some robustness tables (e.g., placebo and leave-one-out) into the appendix to streamline the main text while ensuring they remain easily accessible.

Addressing these suggestions would substantially bolster confidence in the causal interpretation and illuminate the mechanisms behind the “reclassification response.”
